PCPA | Jotup

Sonoco Releases 2023 Corporate Sustainability Report Detailing Progress on Sustainability Initiatives

Retrieved on:

화요일, 4월 23, 2024

Science, Container, Better Life, Task force, PCPA, Sustainability Accounting Standards Board, TCFD, Geography, GRI, ESG, Sustainability accounting, Recycling, Corporate sustainability, Renewable energy

HARTSVILLE, S.C., April 23, 2024 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”) (NYSE:SON), one of the largest global sustainable packaging companies, today released its 2023 Corporate Sustainability Report which highlights progress made in support of its environmental, social and governance (ESG) initiatives.

Key Points:

HARTSVILLE, S.C., April 23, 2024 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”) (NYSE:SON), one of the largest global sustainable packaging companies, today released its 2023 Corporate Sustainability Report which highlights progress made in support of its environmental, social and governance (ESG) initiatives.
This report was prepared in reference to the Global Reporting Initiative (GRI) Standards and the Sustainability Accounting Standards Board (SASB) Containers and Packaging 2018 Sustainability Accounting Standard.
We continued to make progress during the year toward our sustainability and corporate responsibility goals, which are designed to advance Sonoco’s purpose: Better Packaging.
I want to thank them and all our stakeholders for your efforts and support of our sustainability and corporate responsibility goals.”
For detailed information on the frameworks and guidelines used to measure and report on the economic, environmental, social and governance standards, download our 2023 Corporate Sustainability Report at https://www.sonoco.com/na/sustainability/impact/reports .

MITSUBISHI TANABE PHARMA CANADA ANNOUNCES THAT COMPANY'S ORAL TREATMENT FORMULATION FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) HAS BEEN ADDED TO THE PROVINCIAL DRUG PLAN IN ONTARIO

Retrieved on:

화요일, 8월 1, 2023

RADICAVA® Oral Suspension was authorized by Health Canada on November 8, 2022.

Key Points:

RADICAVA® Oral Suspension was authorized by Health Canada on November 8, 2022.
To date, it is estimated that the majority of private insurance plans in the country cover RADICAVA® Oral Suspension.
MTP-CA continues to have discussions with other provinces, territories and federal agencies regarding the listing of RADICAVA® Oral Suspension under additional publicly funded drug programs.
The reimbursement criteria for RADICAVA® Oral Suspension are the same as for RADICAVA® IV, which can be found on the Ontario Ministry of Health's Exceptional Access Program webpage.

Biosimilar BYOOVIZ™ now reimbursed in Quebec to treat serious retinal disorders

Retrieved on:

목요일, 7월 6, 2023

Retina, AMD, PCPA, Pan-Canadian Pharmaceutical Alliance, Diabetic retinopathy, Patient, Physician, Ranibizumab, Health, Health Canada, Safety, Pharmaceutical industry

TORONTO, July 6, 2023 /CNW/ - Biogen Canada Inc. is pleased to announce that Quebec has become the first province to reimburse PrBYOOVIZ™ (ranibizumab injection), an anti-vascular endothelial growth factor (anti-VEGF) biosimilar therapy for certain eye conditions affecting the retina.

Key Points:

TORONTO, July 6, 2023 /CNW/ - Biogen Canada Inc. is pleased to announce that Quebec has become the first province to reimburse PrBYOOVIZ™ (ranibizumab injection), an anti-vascular endothelial growth factor (anti-VEGF) biosimilar therapy for certain eye conditions affecting the retina.
BYOOVIZ, which references PrLUCENTIS®, is the first biosimilar available in Canada to treat retinal vascular disorders including neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema.
"Our experience with biologic therapies runs deep and is part of our commitment to advance patient care with life-changing therapies.
We are proud to provide a high quality, cost-effective treatment option for retinal vascular disorders, and look forward to continuing to work with the other provinces to provide greater public formulary access to BYOOVIZ across the country."

Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS

Retrieved on:

목요일, 6월 15, 2023

“Today marks a major milestone for people living with ALS and their caregivers in Canada.

Key Points:

“Today marks a major milestone for people living with ALS and their caregivers in Canada.
Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis, and eventually death.
ALBRIOZA received approval with conditions from Health Canada in June 2022, marking the first regulatory approval for ALBRIOZA issued to Amylyx worldwide.
We believe there are opportunities to streamline the multiple steps and lengthy processes involved in achieving public reimbursement for treatments like ALBRIOZA in Canada.

FORUS Therapeutics Inc and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for XPOVIO(R)(selinexor)

Retrieved on:

수요일, 5월 24, 2023

Letter of intent, Nuclear transport, PCPA, Multiple myeloma, XPO1, Myeloma Canada, SINE, Pan-Canadian Pharmaceutical Alliance, Dexamethasone, LOI, Bortezomib, Patient, Master of Science, News, Health insurance, Pharmaceutical industry

Oakville, Ontario--(Newsfile Corp. - May 24, 2023) - FORUS Therapeutics Inc ("FORUS") and the pan-Canadian Pharmaceutical Alliance ("pCPA") have completed negotiations with a Letter of Intent (LOI) for XPOVIO®(selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.

Key Points:

Oakville, Ontario--(Newsfile Corp. - May 24, 2023) - FORUS Therapeutics Inc ("FORUS") and the pan-Canadian Pharmaceutical Alliance ("pCPA") have completed negotiations with a Letter of Intent (LOI) for XPOVIO®(selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.
This is a significant milestone to ensure that Canadian MM patients have broad and equitable access to XPOVIO," said Kevin Leshuk, President and CEO of FORUS.
"This is exciting news for the MM community across Canada," said Martine Elias, MSc, Executive Director, Myeloma Canada.
This new treatment regimen provides patients with a unique, effective oral option and meets many of the treatment needs of the myeloma patient community."

Canada's Generic Pharmaceutical Industry Supports Improved Access to Prescription Drug Coverage for Canadians

Retrieved on:

목요일, 4월 7, 2022

API, Transport, Plasma protein binding, Pan-Canadian Pharmaceutical Alliance, Prescription, Element, Industry, Association for Accessible Medicines, COVID-19, CGPA, Federation, PCPA, Pharmaceutical industry, Health insurance

Making prescription drugs more affordable and accessible is the key value proposition of Canada's generic pharmaceutical industry.

Key Points:

Making prescription drugs more affordable and accessible is the key value proposition of Canada's generic pharmaceutical industry.
The ongoing sustainability of our health-care system and drug benefit plans is highly dependent on the increased use of generic prescription medicines.
Governments and stakeholders must now take steps to strengthen the domestic industry and optimize how generic prescription medicines are supplied to Canadians.
The Canadian Generic Pharmaceutical Association (CGPA) is the national association representing Canada's generic pharmaceutical industry.

Government of Canada taking action to further protect Canadians and the environment from the risks of pesticides

Retrieved on:

월요일, 3월 21, 2022

This review follows the Government of Canada's August 4 announcement, which highlighted that Health Canada will begin a review of specific provisions of the Pest Control Products Act.

Key Points:

This review follows the Government of Canada's August 4 announcement, which highlighted that Health Canada will begin a review of specific provisions of the Pest Control Products Act.
The Government of Canada is committed to continuing to make decisions based on the best science available.
"We know that reducing pesticide risks will protect human health as well as the environment that surrounds us.
"We are committed to ensuring that pesticides used in Canada are safe for human health and the environment.

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

Retrieved on:

화요일, 2월 15, 2022

"This is encouraging news for the CPFF community across Canada," says Sharon Lee, executive director of the Canadian Pulmonary Fibrosis Foundation (CPFF).

Key Points:

"This is encouraging news for the CPFF community across Canada," says Sharon Lee, executive director of the Canadian Pulmonary Fibrosis Foundation (CPFF).
Founded in 1885 and family-owned ever since Boehringer Ingelheim takes a long-term perspective.
The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario.
Boehringer Ingelheim employs approximately 600 people across Canada.

EMD Serono's Mavenclad and Novartis' Kesimpta Emerging as Growth Brands After Eventful 2021 for the Multiple Sclerosis Market in Canada, According to Spherix Global Insights

Retrieved on:

월요일, 12월 6, 2021

Insights uncovered shifts in physicians' perceptions and self-reported prescribing patterns across disease-modifying therapy (DMT) brands (and implications within drug classes) driven by these market events.

Key Points:

Insights uncovered shifts in physicians' perceptions and self-reported prescribing patterns across disease-modifying therapy (DMT) brands (and implications within drug classes) driven by these market events.
The dynamics in Canada will unfold quite differently, as generics entered the market while Vumerity is still under Health Canada review.
New prescription share patterns suggest that Genentech's Ocrevus, Kesimpta, and EMD Serono's Mavenclad will experience some of the strongest near-term growth.
Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence.

Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta

Retrieved on:

수요일, 11월 3, 2021

(CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement ("PLA") with Alberta Minister of Health, for the listing and public reimbursement of Enerzair Breezhaler and Atectura Breezhaler, its two innovative asthma therapies, on the Alberta Drug Benefit list effective November 1, 2021.

Key Points:

(CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement ("PLA") with Alberta Minister of Health, for the listing and public reimbursement of Enerzair Breezhaler and Atectura Breezhaler, its two innovative asthma therapies, on the Alberta Drug Benefit list effective November 1, 2021.
"Expanding access and reimbursement for Enerzair and Atectura throughout Canada is a key milestone for our respiratory program.
As previously disclosed, Enerzair and Atectura are also currently listed for reimbursement under private payer health plans which represent all together 85% of privately covered lives accross Canada.
About Valeo Pharma Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology, Neurodegenerative Diseases, Oncology and other specialty products.